Feza Remzi, MD
Colon & Rectal Surgery · New York, NYNPI 1952337040
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 46.4% of the total. Reporting peaked in 2021 at $2,815 and has fallen 79.2% since, to $585 in 2025.
Across 95 payments — averaging $50.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$832
- AbbVie$556
- Intuitive Surgical$421
- Bristol Myers Squibb$203
- Dilon Technologies, Inc.$159
- plus $391 from 8 others
What the payments were for
- Consulting fees$2,36049%
- Travel & lodging$2736%
- Food & beverage$2,15145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $2,222 |
| Johnson & Johnson(3 entities) | 7 | $832 |
| AbbVie | 22 | $556 |
| Intuitive Surgical | 8 | $421 |
| Bristol Myers Squibb | 10 | $203 |
| Dilon Technologies, Inc. | 1 | $159 |
| Nestle Healthcare Nutrition Inc. | 4 | $107 |
| Lilly USA, LLC | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Organon | 2 | $46 |
| Ferring Pharmaceuticals Inc. | 1 | $38 |
| AstraZeneca | 1 | $33 |
| Medtronic | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enseal$620
- Harmonic$620
- Da Vinci Surgical System$252
- HemoBlast Bellows$159
How this compares
$4,783 in reported general payments places this provider in the 70th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other colon & rectal surgery in New York
- Sanghyun KimNew York$154K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- David SchwartzbergNew York$26K
- Richard WhelanNew York$23K
- Alessandro FicheraNew York$20K
- Juliet RayNew York$17K
- Cary AaronsNew York$16K
- Debbie BakesNew York$15K
- Parul ShuklaNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.